Pretomanid is the third new medicine for drug-resistant tuberculosis (DR-TB) to be approved by a stringent regulatory authority in the past decade and the second drug in a class of medicines called nitroimidazoles. It was approved by the United States Food and Drug Administration in August 2019.

GDF can supply pretomanid as part of the combination regimen with bedaquiline and linezolid (e.g., the BPaL regimen). Programmes procuring pretomanid will be requested to complete a one-page form confirming pretomanid will be implemented in alignment with WHO recommendations and rapid communication.

For questions related to ordering pretomanid, please contact GDF at gdf@stoptb.org